Kornimate/medical-research-clean huggingface dataset:
cognitive dysfunction in ms: using altered brain oscillation to link molecular mechanisms with clinical outcomes

Conditions: Pediatric Multiple Sclerosis

Summary: up to 65% of patients with multiple sclerosis (ms) experience cognitive dysfunction. diminution of mental capacity has a pervasive and profound impact on their quality of life. subtle changes in white matter predict cognitive changes in these patients but how this disrupts brain function remains unclear. development of effective therapeutics to restore normal cognition hinges on elucidating these functional changes. the investigators seek to uncover the patho-physiological basis for cognitive decline in ms. the investigators hypothesize that cognitive decline originates from disrupted gamma oscillations and that gamma oscillations are disrupted by molecular changes triggered by demyelination.


Eligibility criteria:
inclusion criteria (\*applicable to controls): 1. must be between 6 and 17 years and 11 months of age\*; 2. have a diagnosis of ms according to the revised mcdonald diagnostic criteria and/or international pediatric ms study group criteria; 3. has english language knowledge at the level needed to complete clinical questionnaires (4th grade level).\* exclusion criteria (\*applicable to controls): 1. neurological comorbidity.\*; 2. relapses or requires treatment with steroids within 30 days from enrollment; 3. is pregnant at the time of enrollment.\*; 4. has any metal parts in their body (i.e. cochlear (ear) implant, metal braces (dental fillings are o.k.).\*; 5. is younger than 6 years of age.\*; 6. is older than 18 years of age.\*; 7. has prior history of traumatic brain injury, neurological disorder, cerebral palsy, developmental delay or learning disability.\*; 8. requires sedation for brain scanning.\*; 9. is claustrophobic, as brain scanning requires children to enter a tunnel in the mri machine.\*
treatment of allergic rhinitis and chronic polypous rhinosinusitis with olfactory mucosa-derived mesenchymal stem cells

Conditions: Allergic Rhinitis; Rhinosinusitis Chronic

Summary: treatment of patients with allergic rhinitis and chronic polypous rhinosinusitis with olfactory mucosa-derived mesenchymal stem cells

during the implementation of the project, the methods for the treatment of allergic rhinitis and chronic polypous rhinosinusitis with olfactory mucosa-derived mesenchymal stem cells will be developed. the positive outlook for the effectiveness of mscs is due to the following: * knowledge of the leading role of immunopathogenetic mechanisms in the development of allergic rhinitis and chronic polypous rhinosinusitis and the pronounced immunomodulating properties of mscs; * the ability of mscs to reduce the production of proinflammatory cytokines and suppress immune inflammation; * positive results of preclinical studies of the method of treatment of diseases accompanied by over-activation of the immune system, including autoimmune diseases, in animals and the first clinical studies in patients.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of allergic rhinitis or chronic polyposis rhinosinusitis * the patient can read, understand, follow the examination procedures and complete, if necessary, the required documentation * written informed consent exclusion criteria: * the presence of any malignant tumor within the last 5 years * acute or chronic diseases in the stage of decompensation * chronic infectious diseases: hiv, viral hepatitis b, c, tuberculosis * patients who are pregnant, breastfeeding, or fertile patients who are not using adequate contraceptive methods * chronic and protracted mental disorders, all diseases with the presence of the syndrome of dependence on alcohol, drugs and psychoactive substances, any other condition that makes the patient unable to understand the nature, extent and possible consequences of the study or, in the opinion of the researcher, prevents the patient from observing and performing protocol * patients are unable or unwilling to give written informed consent and / or follow research procedures * any other medical condition that, in the opinion of the investigator, may be associated with an increased risk to the patient or may affect the outcome or evaluation of the study
vibration training in chronic obstructive pulmonary disease (copd)-patients during a three-week rehabilitation

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the aim of this study is to investigate the change of physical activity in copd-patients performing a whole body vibration training additional to a standard three-week rehabilitation program in comparison to patients performing merely a standard rehabilitation program.


Eligibility criteria:
inclusion criteria: * chronic obstructive pulmonary disease iii/iv exclusion criteria: * severe exacerbations in the last 4 weeks prior to begin of study (definition of exacerbation: symptoms on more than 3 days with a relevant change in drug therapy (cortisone, antibiotics)) * severe disease other than copd, that could influence the results of the study * abuse of alcohol or drugs * simultaneously participation in another study * tachypnea (\>30/min) * severe exacerbation during rehabilitation * cardiac insufficiency (nyha iv) * myocardial infarction during the last 6 weeks * mental-health problem * pregnancy * known hiv-infection * slipped disk * acute discopathy * acute thrombosis * implants in trained regions of the body (lower extremities) * acute inflammation of the locomotor system, active arthrosis or rheumatoid arthritis * acute tendinopathy in trained regions of the body * acute hernia * fresh fractures, wounds or scars in trained regions of the body * gallstones or stones in the urinary tract collection system

Keywords: copd iii/iv activity monitoring sensewear vibration training galileo pulmonary rehabilitation
a dose-ranging study of drm01 in subjects with acne vulgaris

Conditions: Acne Vulgaris

Summary: the objectives of this study are to assess the safety and efficacy drm01 topical gel compared to vehicle in patients with acne vulgaris.


Eligibility criteria:
inclusion criteria: * signed informed consent. * male or non-pregnant, non-lactating females. * age ≥ 18 years. * clinical diagnosis of facial acne vulgaris defined as: * at least 20 inflammatory lesions * at least 20 non-inflammatory lesions * investigator global assessment of 3 or greater. exclusion criteria: * active cystic acne or acne conglobata, acne fulminans, and secondary acne. * two or more active nodulocystic lesions. * screening clinical chemistry or hematology laboratory value that is considered clinically significant, in the opinion of the investigator. * abnormal findings on screening ecg, deemed clinically significant, by the investigator. * subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 30 days or 5 half-lives (whichever is longer) of the baseline visit. * subjects who are a poor medical risk because of other systemic diseases or active uncontrolled infections, in the opinion of the investigator. * treatment with over-the-counter topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids, α-hydroxy/glycolic acid on the face within 2 weeks prior to baseline. * treatment with systemic corticosteroids (use of intranasal and inhaled corticosteroids allowed for seasonal allergies and asthma) within 4 weeks prior to baseline. * treatment with systemic antibiotics or systemic anti-acne drugs or systemic anti-inflammatory drugs within 4 weeks prior to baseline. * prescription topical retinoid use on the face within 4 weeks of baseline (e.g., tretinoin, tazarotene, adapalene). * treatment with a new hormonal therapy or dose change to existing hormonal therapy within 12 weeks prior to baseline. dose and frequency of use of any hormonal therapy started more than 12 weeks prior to baseline must remain unchanged throughout the study. hormonal therapies include, but are not limited to, estrogenic and progestational agents such as birth control pills. * prior use of androgen receptor blockers (such as spironolactone or flutamide). * oral retinoid use (e.g., isotretinoin) within 12 months prior to baseline or vitamin a supplements greater than 10,000 units/day within 6 months of baseline. * facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 8 weeks or during the study.
selection criteria in endovascular thrombectomy and thrombolytic therapy (secret) study: development of patient selection criteria using ct images and accompanying diseases for efficient intravenous thrombolytic and intra-arterial recanalization therapy in acute ischemic stroke

Conditions: Ischemic Stroke

Summary: use of intravenous (iv) thrombolysis and intra-arterial (ia) recanalization treatment has been rapidly increasing, however, despite of the treatment, recanalization rates are 22.6 - 70% and only 30-50% of patients show meaningful clinical improvements. mechanisms of futile recanalization may include 1) large ischemic core, 2) poor collateral, and 3) presence of comorbidity. in this regards, developing selection criteria using acute stroke imaging and comorbidity is warranted. investigators will recruit the consecutive acute stroke patients who received iv thrombolysis and/or ia recanalization treatment. this study will perform with prospective design to develop ct-based clot, core and collateral scores and a comorbidity index for selecting stroke patients who are at high risks by the treatment. investigators will firstly establish the ct-based scores and comorbidity index using a pre-existing cohort database. using these ct-based and comorbidity index, investigators will validate them in a multi-center prospectively cohort. in addition, investigators will assess the cost-effectiveness of selecting patients based on the comorbidity index.


Eligibility criteria:
inclusion criteria: * age ≥20 years old * acute ischemic stroke patients who underwent ct angiographies before iv thrombolysis and/or ia recanalization treatment * patients who give an informed consents for participation in the study or the legal representative or immediate family give informed consent on behalf of patients in case of difficulty to decide study enrollment. exclusion criteria: * age \<20 years old * acute ischemic stroke patients who did not receive iv thrombolysis and/or ia recanalization treatment * no informed consents from patients
a prospective randomised control trial to study the effectiveness of a health service innovation using a modified virtual ward model to prevent unscheduled readmission of high risk patients

Conditions: Chronic Diseases

Summary: the investigators conducted an open randomized control study of patients who received the transitional care program versus patients who received usual care at the singapore general hospital from aug 2011 to sept 2012.

the investigators conducted an open randomized control study of patients who received the transitional care program versus patients who received usual care at the singapore general hospital from aug 2011 to sept 2012.

Eligibility criteria:
inclusion criteria: * patients with 2 or more unscheduled admission in the last 90 days to selected medical departments * lace score of ≥10. exclusion criteria: * non-residents * no telephone contact or a resident address * residing in long term care facilities.

Keywords: readmission chronic diseases
risk factors for ponv in patients undergoing hysteroscopic surgery

Conditions: Gynecologic Nursing; Postoperative Complications

Summary: the purpose of this study was to construct and validate a risk prediction model for ponv in patients undergoing hysteroscopic day-case surgery.

this study predicted the risk of postoperative nausea and vomiting in patients undergoing day-case hysteroscopic surgery by constructing and validating a web-based dynamic nomogram.

Eligibility criteria:
inclusion criteria: * female patients undergoing hysteroscopic day-case surgery and aged 18 years. exclusion criteria: * patients with intraoperative change of surgical method and unstable postoperative vital signs.

Keywords: ponv risk factor nursing
high-dose intravitreal injection of ganciclovir for the treatment of cmvr in hiv-negative patients

Conditions: Infection Viral; Uveitis, Posterior

Summary: this prospective, non-randomized, non-controlled clinical trial was conducted to examine the clinical outcomes achieved by using initial high-dose intravitreal ganciclovir injections of ganciclovir in treating cytomegalovirus (cmv) retinitis in patients without human immunodeficiency virus (hiv) infection.

cytomegalovirus retinitis (cmvr) is a serious vision-threatening disease. intravitreal antiviral drug delivery was used as first-line treatment in several studies when systematic injection has been ruled out. the reported dose of intravitreal injections of ganciclovir (ivg) varied from 200 μg/0.1 ml to 5mg/0.1 ml in patients with aids. there was no consensus on the dose of ganciclovir in the treatment of cmvr in hiv-negative patients. previous work showed the safety and the efficacy of 1mg ivg. the investigators proposed that a higher dose of ganciclovir (6mg/0.1ml) for the first injection followed by lower dose for maintenance may indicate a better result. therefore, this study was performed to evaluate the therapeutic effect and safety of initial high-dose ivg for cmvr in hiv-negative patients.

Eligibility criteria:
inclusion criteria: * patients with cmvr by ophthalmological examination * positive cmv-dna in aqueous humor approved by real-time pcr. * hiv-negative. exclusion criteria: * diabetic retinopathy, * glaucoma. * optic neuritis.

Keywords: cytomegalovirus retinopathy high-dose ganciclovir intravitreal injection
caes for internal hemorrhoids and rectal prolapse

Conditions: Internal Hemorrhoid; Rectal Prolapse

Summary: cap-assisted endoscopic sclerotherapy (caes) is a new interventional therapy for internal hemorrhoids and rectal prolapse under colonoscopy. however, the long-term efficacy and safety of caes in the treatment of internal hemorrhoids and rectal prolapse are still not clear due to the lack of large sample studies. therefore, a nationwide multi-center, large sample, prospective and cohort study was designed to evaluate the efficacy and safety of caes in the treatment of internal hemorrhoids and rectal prolapse, to provide reliable evidence for popularization of this minimally invasive technology.

caes is an innovative endoscopic sclerotherapy procedure which is different from traditional method. firstly, the cap added to the front of colonoscope can fully expose the operating field. secondly, before or during the opportunity of caes, endoscopist can perform endoscopic differentiation diagnosis (such as tumors, inflammatory bowel disease and others induced hematochezia), endoscopic therapy within lower-gut based on the same colon preparation, thus saving patients' medical cost, physical and mental pain. the last but not least, specially designed length of endoscopic injection needle (eg.10-20 mm) was used in caes could be helpful for accurately controlling the injection angle, direction, depth under direct vision and to avoid iatrogenic injury due to ectopic injection.the core value of caes for internal hemorrhoids and rectal prolapse is to provide precise therapy, reduce the iatrogenic injuries, avoid pain during and after therapy. our pilot studies demonstrated that caes based on long injection needle is an effective, safe, convenient operation technique. 100% of participants underwent caes showed sustained clinical efficacy within the 3-month follow-up, with no severe or obvious complications related to caes. however, the long-term efficacy and safety of caes in the treatment of internal hemorrhoids and rectal prolapse need to be confirmed by further large sample real world studies.

Eligibility criteria:
inclusion criteria: 1. grade i-iii internal hemorrhoids (with or without external hemorrhoids) or/and recal prolapse. 2. patients with bowel preparation. exclusion criteria: 1. history of anoscopic/endoscopic sclerotherapy. 2. acute thrombotic hemorrhoids or grade iv internal hemorrhoids. 3. anal stenosis, perianal and perirectal abscess, anal fissure, fistula, fecal incontinence and other severe complications (such as severe anal pain). 4. inflammatory bowel disease. 5. full-thickness rectal prolapse through the anus. 6. acute diarrhea in the past 24 hours. 7. hypertensive with uncontrolled blood pressure. 8. cerebrovascular accident. 9. blood coagulation dysfunction. 10. pregnant women. 11. mental disorders. 12. decompensated cirrhosis.

Keywords: cap-assisted endoscopic sclerotherapy internal hemorrhoid rectal prolapse
acute hospital care at home for people living with dementia

Conditions: Emergency Department Visit; Home Care Services; Dementia

Summary: the investigators will perform a parallel-group multicenter randomized controlled trial of a 1-year pre-enrolled acute hospital care at home intervention vs usual care for people living with dementia. patients will be randomized only after eligibility determination and after the family caregiver agrees to enroll; people living with dementia will assent when able. patients will be allocated in a concealed fashion to the control and intervention groups in randomly selected block sizes of 4 or 6 in 4 strata reflecting their functional status (activities of daily living: 0, 1, 2-3, 4-6). although family and clinicians cannot be blinded, the investigators will blind the data collectors and assessors.


Eligibility criteria:
inclusion criteria: * diagnosis of moderate or severe dementia (as ascertained by the quick dementia rating system; qdrs) * resides in a private or assisted living residence with or nearby (\<15min travel time) to a family caregiver * resides within the mass general brigham (mgb) home hospital catchment area * has had at least 1 hospitalization in the last 12 months. exclusion criteria: * no functioning utilities, such as no working heat (october-april), no running water, or no electricity. * resides in skilled nursing facility * resides in group home * domestic violence screen positive * in police custody * family caregiver unable to initiate or maintain communication with care team * end-stage renal disease on hemodialysis * on methadone requiring daily pickup of medication * active substance use disorder, without functioning treatment plan * psychiatric diagnosis that would prohibit successful home hospital care * acute delirium without explanation or without the ability to manage at home * patients with cancer requiring consistent hospital-based treatments * cannot ambulate to bedside commode with assistance present in the home (if different from baseline), unless home-based aides are available
the effect of suboccipital release technique in individuals with anxiety

Conditions: Anxiety; Trapezius Muscle Strain; Pain

Summary: the purpose of this study is to determine the immediate effect of the suboccipital release technique on trapezius muscle pain threshold, muscle activation, and anxiety level in individuals with anxiety.thirty-six people with anxiety symptoms were included in the study. these people were divided into two groups, 18 control group and 18 treatment group. upper trapezius muscle pain threshold, muscle activation and anxiety levels were evaluated. the experimental group received a single session of suboccipital release technique. the control group received a single session of sham suboccipital release. the evaluations were performed before and immediately after the treatment.the suboccipital release technique can increase the trapezius muscle upper part pain threshold and concentric muscle activation immediately after the application in individuals with anxiety.


Eligibility criteria:
inclusion criteria: * being over the age of 18 * agree to participate the study exclusion criteria: * use psychiatric, analgesic and antispasmodic drugs
the effect of minimal flow sevoflurane anesthesia

Conditions: Anesthesia; Functional; Anesthesia Awareness

Summary: our aim is to investigate the effect of minimal flow anesthesia with sevoflurane on hemodynamics and arterial blood gas parameters in laparoscopic cholecystectomy operations.

introduction: low-flow anesthesia techniques have regained popularity in recent years with the development of low solubility volatile agents such as sevoflurane and desflurane, and modern anesthesia devices. reducing the flow of fresh gas as much as possible will reduce the amount of volatile agent used, thus preventing air pollution, providing lower costs, and also preserving heat and moisture in the respiratory tract by using rebreathing systems. laparoscopic surgery is superior to open surgical techniques due to its minimally invasive nature, less postoperative pain, less incidence of wound infections, shortening the hospitalization, and allowing patients to return to their normal lives sooner after the operation. our aim is to investigate the effect of minimal flow anesthesia with sevoflurane on hemodynamics and arterial blood gas parameters in laparoscopic cholecystectomy operations. material and method: seventy patients with asa (american society of anesthesiologists) class i-ii between the ages of 18-65 undergoing elective laparoscopic cholecystectomy were included in the study. after the patients were randomly selected by computer, they were divided into two equal groups as group m (minimal flow anesthesia group) with fresh gas flow 0,5 l.min-1 and group c (high flow anesthesia/ control group) with fresh gas flow 4 l.min-1. in both groups. demographic data, duration of anesthesia, operation times, recovery times, hemodynamic parameters and arterial blood gas parameters of all patients were recorded. the patient data collected in both groups were compared statistically.

Eligibility criteria:
inclusion criteria: * asa (american society of anesthesiologists) class i-ii * the operation time between 60-180 minutes exclusion criteria: * severe cardiac disease * copd (chronic obstructive pulmonary disease) * severe liver and kidney disease, * diabetes mellitus * morbid obesity * alcohol and/or drug addiction * risk or history of malignant hyperthermia * pregnancy and lactation * emergency cases * operation time less than 60 minutes and longer than 180 minutes

Keywords: minimal flow anesthesia laparoscopic cholecystectomy
evaluation of co intoxication rate, by capillary hbco

Conditions: Carbon Monoxide Intoxication

Summary: the main goal of cocap is to compare cohb (carboxyhemoglobin) levels measured from venous or arterial samples with those measured from capillary samples in patients suspected of carbon monoxide intoxication.patient participation in the study will be limited to capillary sampling (approx. 5-15 minutes).


Eligibility criteria:
inclusion criteria: * adult patient admitted to emergency department * presenting one or more clinical signs (asthenia, headache, nausea, vomiting, loss of consciousness, etc.) and a history compatible with co intoxication (collective symptoms, notion of smoke, activation of a detector, etc.). exclusion criteria: * minors * patients under protective supervision (safeguard of justice, curatorship, guardianship) * incarcerated patients * pregnant or breast-feeding women * patients refusing to take part in the study

Keywords: intoxication carbon monoxyde carboxyhemoglobin cohb carboxyhemoglobin capillary